Shulman Joseph 4
4 · RHYTHM PHARMACEUTICALS, INC. · Filed Nov 3, 2025
Insider Transaction Report
Form 4
Shulman Joseph
Chief Technical Officer
Transactions
- Exercise/Conversion
Stock Options (Right to Buy)
2025-10-30−9,748→ 0 totalExercise: $30.66Exp: 2031-02-10→ Common Stock (9,748 underlying) - Exercise/Conversion
Common Stock
2025-10-30$30.66/sh+9,748$298,874→ 18,257 total - Sale
Common Stock
2025-10-30$115.24/sh−9,748$1,123,398→ 8,509 total
Footnotes (3)
- [F1]The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024.
- [F2]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.00 to $115.73 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The stock option is fully vested.